Posts

Showing posts with the label ADCs

Unleashing the Potential: The Evolving Landscape of Antibody-drug conjugates in Cancer Treatment

Image
Antibody-drug conjugates have emerged as a revolutionary class of therapies in the field of oncology. By combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs, Antibody-drug conjugates offer a targeted approach to cancer treatment. In this blog, we will provide an overview of the current and future treatment landscape of Antibody-drug conjugates in oncology, exploring their mechanism of action and potential applications. Understanding Antibody-Drug Conjugates: Antibody-drug conjugates are designed to deliver a cytotoxic drug directly to cancer cells by attaching it to a monoclonal antibody. The antibody recognizes and binds to specific markers on the cancer cells, allowing the drug to be selectively delivered to the tumor site. This targeted approach reduces damage to healthy cells and enhances treatment efficacy. Current Marketed Antibody-drug conjugates in Oncology: Several Antibody-drug conjugates have gained approval and are making a significant im...